Tectonic surges on phase 1b data for pulmonary hypertension asset

[Percentage Symbol with Slash Transforming into Upward Growth Graph Representing Financial Gains and Market Trends]
J Studios

* Tectonic Therapeutic (TECT) has skyrocketed ~29% in after-hours trading Wednesday after posting positive phase 1b results for TX45, its candidate for pulmonary hypertension in heart failure with reduced ejection fraction ("PH‑HFrEF").
* Patients in the Part B segment of the trial didn't experience any serious or severe adverse events, clinically significant changes in blood pressure, or immune related reactions.
* A total of 14 patients were enrolled in Part B. TX45, a long-acting, Fc-relaxin fusion protein, led to significant improvements in left heart function and pulmonary hemodynamics.
* Tectonic is currently conducting a phase 2 trial of TX45 known as APEX, with enrolled patients treated over 24 weeks. Topline results are expected in 2026.
* Company shares soared 40% [https://seekingalpha.com/news/4400674-tectonic-stock-jumps-trial-data-tx45] after it released data from Part A of the phase 1b trial back in January.

MORE ON TECTONIC THERAPEUTIC

* Tectonic Therapeutic a new outperform at Oppenheimer on heart drug asset [https://seekingalpha.com/news/4491922-tectonic-therapeutic-new-outperform-oppenheimer-heart-drug-asset]
* Seeking Alpha’s Quant Rating on Tectonic Therapeutic [https://seekingalpha.com/symbol/TECX/ratings/quant-ratings]
* Historical earnings data for Tectonic Therapeutic [https://seekingalpha.com/symbol/TECX/earnings]
* Financial information for Tectonic Therapeutic [https://seekingalpha.com/symbol/TECX/income-statement]